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ABSTRACT
Background: The Asthma Health Questionnaire (AHQ)-Japan is useful for assessing quality of life (QOL) in
Japanese patients with asthma. However, no studies have compared the AHQ-Japan to other QOL instru-
ments.
Methods: The AHQ-33-Japan and the Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36)
were completed simultaneously by 126 Japanese patients with asthma (48 men, 78 women; 58.1 ± 17.3 years
of age), and the data were compared.
Results: Poor negative correlations (correlation coefficient (r) = −0.20 to −0.44, P < 0.05) were observed for
38 combinations of the subscales of these QOL instruments. As the severity of the patients’ asthma increased,
the scores of most subscales of both QOL instruments became worse. However, the AHQ-33 was more sensi-
tive for severity than the SF-36. On logistic regression analysis, high Asthmatic Symptoms, Factors which
Worsened Symptoms, Emotion, Daily Activity, and Social Activity subscale scores, as well as a high total 32-
item score, of the AHQ-33 were associated with an increased risk of moderate to severe asthma. On the other
hand, only the Physical functioning subscale score of the SF-36 was associated with an increased risk of mod-
erate to severe asthma.
Conclusions: Our results show that the AHQ-33 is useful as a disease-specific QOL instrument in Japanese
patients with asthma and that it is better than the SF-36, which is a generic QOL instrument. In the future, the
AHQ-33 should be compared to other asthma-specific questionnaires.
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INTRODUCTION
Asthma is a chronic disease that requires long-term
management and has a major effect on patients’ ac-
tivities of daily living. Since asthma is recognized as a
disease of the airways, anti-inflammatory drugs, pri-
marily inhaled corticosteroids, are recommended,
and guidelines for the diagnosis and treatment of
asthma have been formulated.1 To determine
whether asthma patients’ health status is stable, it is
necessary to evaluate their quality of life (QOL),
which includes not only subjective symptoms, peak
expiratory flow (PEF), and spirometry, but also the
patients’ economic burden and their feeling of satis-
faction. The Medical Outcomes Study Short-Form 36-
Item Health Survey (SF-36)2-4 is now widely used as a
generic health-related quality of life (HRQOL) ques-
tionnaire. The validity and reliability of the SF-36
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have also been reported in asthma,2,5 and the SF-36
has also been used as an assessment tool in many
QOL studies of asthma patients.6-9
The Asthma Health Questionnaire (AHQ) was
originally developed as the AHQ-37, which included
36 items and a Face Scale;10,11 it is a disease-specific
HRQOL questionnaire that was developed in Japan.
The AHQ-37 has been shown to have clinical validity,
and it is also reliable and valid for discriminative pur-
poses; thus, it can be used with confidence in clinical
research.10 However, the AHQ-33 is now widely used,
since 4 inappropriate items were eliminated by multi-
trait analysis.11 The AHQ-33 has 6 subscales (Asth-
matic Symptoms, Factors which Worsened Symp-
toms, Emotion, Daily Activity, Social Activity, and
Economics), which consist of a total of 32 items
(graded 0 to 4), and 1 Face Scale (graded 1 to 5). A
higher score on the AHQ-33 reflects a worse health
status with respect to these 33 items, which is the op-
posite of the SF-36 subscales, where a lower score re-
flects a worse health status. We have also confirmed
the validity of the AHQ-33 in an extensive study of
Japanese asthma patients (data not shown).
No studies have compared the AHQ with other
QOL instruments. In the present study, the QOL of
asthma patients in Japan was assessed using the
AHQ-33 and the SF-36. The aim was to identify which
HRQOL disorders cannot be identified by the SF-36
as a generic QOL instrument but can be identified by
the AHQ-33 as a disease-specific QOL instrument.
METHODS
One hundred and forty-nine Japanese patients (67
men, 82 women; 60.1 ± 17.3 years of age) at the
Hashimoto Municipal Hospital were enrolled. All par-
ticipants were required to have been diagnosed as
having asthma by a respiratory physician. The exclu-
sion criteria included: 1) age <15 years; 2) COPD or
other respiratory diseases; and 3) malignant diseases,
cardiac diseases, severe liver dysfunction, severe re-
nal dysfunction, hematological diseases, psychiatric
diseases, or dementia. COPD was diagnosed clini-
cally based on exposure to particles, such as a 10-
pack-year history of tobacco use, emphysema on
chest CT, and other factors. Patients were required to
understand written Japanese in order to be able to
complete the questionnaires and to give their written
informed consent, which indicated that they under-
stood the aim and methods of this clinical study, and
that there would be no disadvantages if they chose
not to participate. This clinical study was approved by
the Ethics committee of the Hashimoto Municipal
Hospital, Hashimoto, Japan, and conformed to the
principles outlined in the Declaration of Helsinki.
The data of 126 patients were used for the final vali-
dation. Asthma severity was classified according to
the Global Initiative for Asthma (GINA) guidelines.1
Etiology was classified based on the presence of
antigen-specific IgE; patients with antigen-specific
IgE were diagnosed as having atopic asthma. Morn-
ing and evening PEFs were determined based on the
mean values obtained 7 days before the questionnaire
survey was completed; the results are reported as the
percentage of the predicted value.12
The AHQ-33-Japan and the SF-36 v2TM Health Sur-
vey (Japanese version) were completed during the
same session. The correlations between the
subscales of the two QOL instruments and the rela-
tionships between their subscales and disease sever-
ity were evaluated.
STATISTICAL ANALYSIS
Spearman’s correlation coefficient was used to ana-
lyze relationships between two variables, and differ-
ences between score means were assessed using the
Steel-Dwass method. The odds ratio (OR) and the
95% confidence interval (CI) were estimated based on
the logistic model; they were used to measure the
strength of the association between disease severity
and each subscale. They refer to the relative risk as-
sociated with moderate to severe asthma for higher
scores (more than the mean score of each subscale)
compared to lower scores. Data are reported as mean
± standard deviation (SD) values, and a p value < 0.05
was considered significant. However, even if the p
value was < 0.05, a correlation coefficient (r) of 0 to ±
0.2 was considered to indicate no correlation.
RESULTS
There were 126 subjects (48 men, 78 women) with a
mean age of 58.1 ± 17.3 years (range: 16―88). The
mean serum IgE level was 338.1 ± 763.8 IUml (n =
97); 52.3% (n = 56) of patients had atopic asthma, and
47.7% (n = 51) had non-atopic asthma. According to
the GINA classification,1 9.5% (n = 12) of patients had
intermittent asthma, 24.6% (n = 31) had mild persis-
tent asthma, 38.9% (n = 49) had moderate persistent
asthma, and 27.0% (n = 34) had severe persistent
asthma. Subjects with a past history of childhood
asthma accounted for 13.7% (16117) of the patients,
while 20.6% (26126) had allergic rhinitis, and 12.9%
(16124) of the patients were ex- or current smokers.
Thirty-seven patients were monitored using a peak
flow meter and had analyzable peak expiratory flow
(PEF) data; their morning %PEF was 78.6% ± 19.8%,
and their evening %PEF was 81.4% ± 18.2%.
The AHQ-33 and the SF-36 subscale scores are
shown as histograms and box and whisker plots in
Figures 1, 2. The box and whisker plots are shown
with quartiles, with the boxes indicating the inter-
quartile ranges (25―75%), the lines within the boxes
indicating the medians, and the diamonds indicating
the sample means and the 95% confidence intervals.
In addition, the overall distribution is shown in terms
of the minimum, 2.5%, 10%, 90%, 97.5%, and the maxi-
mum quartiles. The score distribution was more bi-
AHQ-33 and SF-36 for Asthma
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Fig. 1 The distribution of the AHQ-33 subscale scores. The distribution of each subscale score is shown by a histo-
gram and a box and whisker plot. The ranges for the original scores on each subscale are shown on the vertical axes. 
The horizontal axes show the frequency.
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ased for the AHQ-33 than for the SF-36. The response
rates were high (100% for the AHQ-33 and 99.5% for
the SF-36), and there was some variability in the dis-
tribution. Of the 6 subscales other than the Face
Scale, the Asthmatic Symptoms subscale had the
highest score on the transformed 0―100 score on the
AHQ-33 (19.4 ± 18.2), and the General health
subscale had the lowest score on the SF-36 (50.6 ±
19.1).
Correlations between all combinations of the AHQ-
33 subscales and the SF-36 subscales were examined
due to the interscale correlation of each HRQOL in-
strument and the cross-over of the question item con-
tents between these two instruments (Table 1). Poor
negative correlations (r = −0.20 to −0.44, P < 0.05)
were observed between the subscales of these two in-
struments for 38 combinations: Asthmatic Symptoms
of the AHQ-33 correlated with Physical functioning,
General health, Vitality, and Mental health of the SF-
36; Factors which Worsened Symptoms correlated
with Physical functioning and Vitality; Emotion corre-
lated with General health, Vitality, Social functioning,
and Mental health; Daily Activity correlated with
Physical functioning, Role-physical, Bodily pain, Gen-
eral health, Vitality, and Social functioning; Social Ac-
tivity correlated with Physical functioning, General
health, Vitality, Social functioning, Role-emotional,
and Mental health; Economics correlated with Vital-
ity, Social functioning, and Mental health; the total 32-
item score correlated with Physical functioning, Gen-
eral health, Vitality, Social functioning, and Mental
health; and the Face Scale correlated with all
subscales.
The subscale scores on the two HRQOL question-
naires are shown in Table 2 by severity. With worsen-
ing severity, each subscale score of the AHQ-33 in-
creased, except for the Economics and Face Scale.
The Asthmatic Symptoms, Factors which Worsened
Symptoms, Emotion, and Daily Activity subscale
scores, as well as the total 32-item score, were signifi-
cantly higher in patients with moderate to severe dis-
ease. As disease severity worsened from mild persis-
Muraki M et al.
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Fig. 2 The distribution of the SF-36 subscale scores. The distribution of each subscale score is shown by a histogram 
and a box and whisker plot. The vertical axes and the horizontal axes show the subscale scores/100 and the frequency, 
respectively.
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tent to severe, most SF-36 subscale scores decreased.
The Physical functioning and Bodily pain subscale
scores were significantly lower in patients with se-
vere persistent asthma than in those with mild persis-
tent asthma. However, all SF-36 subscale scores were
lower in patients with intermittent asthma than in
those with mild persistent asthma, but the differences
were not statistically significant. Logistic regression
was also used to evaluate the relationship between
asthma severity and the scores of the two HRQOL in-
struments (Table 3). High Asthmatic Symptoms, Fac-
tors which Worsened Symptoms, Emotion, Daily Ac-
tivity, and Social Activity subscale scores, as well as a
high total 32-item score, of the AHQ-33 (=mean level)
were associated with an increased risk of moderate to
severe asthma (OR (95% CI) = 3.88 (1.67 to 9.90), 3.21
(1.48 to 7.32), 3.31 (1.32 to 9.54), 3.94 (1.65 to 10.58),
2.75 (1.17 to 7.03), and 3.69 (1.59 to 9.43), respec-
tively, p < 0.05), whereas only a low Physical function-
ing subscale score of the SF-36 was associated with
an increased risk of moderate to severe asthma (OR
(95% CI) = 2.47 (1.08 to 6.10), p < 0.05).
The correlations between the two HRQOL instru-
ments’ subscales and morning %PEF or evening
%PEF are shown in Table 4. Morning %PEF corre-
lated with the Factors which Worsened Symptoms
and Daily Activity subscale scores, as well as the total
32-item score, of the AHQ-33 (r = −0.33 to −0.48, p <
0.05), and evening %PEF correlated with the Daily Ac-
tivity subscale score (r = −0.38, p < 0.05). On the
other hand, Morning %PEF correlated with 4 SF-36
subscales, and evening %PEF correlated with 2 SF-36
subscales.
DISCUSSION
More accurate methods of measuring morbidity,
such as QOL measurements, are needed. Asthma is a
chronic disorder that can place considerable restric-
tions on the physical, emotional, and social aspects of
patients’ lives and may affect their careers. Asthma
patients may often be absent from school or work.1
To measure QOL in patients with asthma, the Not-
tingham Health Profile with 45 items and the SF-36
are now widely used and have been validated. The
SF-36 Health Status Questionnaire is based on 36
items selected to represent 8 health concepts. A
AHQ-33 and SF-36 for Asthma
Allergology International Vol 57, No4, 2008 www.jsaweb.jp 343
Table 1 The corelation between subscales of AHQ-Japan and SF-36
p valuerp valuerp valuerp valuer
DA vs.Em vs.FWS vs.AS vs.
＜0.01†－0.430.03－0.20 0.02†－0.20＜0.01†－0.29PF
SF-36
0.02†－0.210.26－0.100.23－0.110.09－0.15RP
＜0.01†－0.270.18－0.120.22－0.110.07－0.16BP
＜0.01†－0.33＜0.01†－0.320.04－0.18＜0.01†－0.31GH
＜0.01†－0.27  0.01†－0.22＜0.01†－0.25＜0.01†－0.31VT
＜0.01†－0.26  0.01†－0.220.12－0.140.07－0.16SF
0.10－0.150.50－0.060.29－0.090.14－0.13RE
0.06－0.17＜0.01†－0.270.03－0.20 0.02†－0.21MH
p valuerp valuerp valuerp valuer
Face scale vs.Total sore of 32 items vs.Ec vs.SA vs.
＜0.01†－0.25＜0.01†－0.310.46－0.070.01†－0.22PF
SF-36
＜0.01†－0.250.11－0.140.78－0.030.10－0.15RP
＜0.01†－0.330.06－0.170.25－0.100.12－0.14BP
＜0.01†－0.41＜0.01†－0.320.14－0.13＜0.01†－0.25GH
＜0.01†－0.43＜0.01†－0.310.02†－0.200.02†－0.21VT
＜0.01†－0.340.01†－0.22＜0.01†－0.25＜0.01†－0.26SF
＜0.01†－0.230.16－0.130.42－0.070.02†－0.21RE
＜0.01†－0.44＜0.01†－0.25＜0.01†－0.23＜0.01†－0.28MH
r, corelation coeficient; AS, Asthmatic symptoms; FWS, Factors which worsend symptoms; Em, Emotion; DA, Daily activity; SA, So-
cial activity; Ec, Economics; PF, Physical functioning; RP, Role-physical; BP, Bodily pain; GH, General health; VT, Vitality; SF, Social 
functioning; RE, Role-emotional; MH, Mental health.
†: p＜0.05 except r of 0 to 土0.2.
Table 2 Scores of subscales in AHQ-Japan and SF-36 according to severity
AHQ-Japan
Face scaleTotal score of32 itemsEcSADAEmFWSASseverity
2.34.80.30.70.20.61.31.9Intermitent
土0.8土4.3土0.9土2.0土0.6土0.9土2.3土1.8
2.315.20.21.20.83.24.45.3Mild persistent
土1.1土17.1土0.6土2.6土1.7土4.5土5.4土5.2
2.319.8†0.51.71.54.8†5.16.2†Moderate persistent
土1.0土20.3土1.1土2.9土2.3土5.8土5.9土6.2
2.424.7†§0.42.02.1†§5.3†6.5†8.5†§Severe persistent
士0.9士19.4士0.7士2.9士2.1士6.6士5.4士5.9
SF-36
MHRESFVTGHBPRPPFseverity
67.158.382.359.949.967.763.980.8Intemitent
土24.5土45.2土13.5土25.0土12.3土25.8土39.0土16.1
72.382.387.964.858.380.976.685.2Mild persistent
土17.6土33.6土13.9土20.1土15.8土22.1土39.2土20.2
69.062.680.462.648.872.567.979.5Moderate persistent
土21.5土44.9土23.8土25.1土21.7土28.2土40.3土23.3
65.463.673.953.846.557.9§64.166.1§¶Severe persistent
土19.1土44.4土23.1土22.5土18.4土30.0土43.3土27.1
AS, Asthmatic symptom; FWS, Factors which worsened symptoms; Em, Emotion; DA, Daily activity; SA, Social activity; Ec, Econom-
ics; PF, Physical functioning; RP, Role-physical; BP, Bodily pain; GH, General health; VT, Vitality; SF, Social functioning; RE, Role-emo-
tional; MH, Mental health.
Data are expressed as mean 士 standard deviation (SD) values. †: p＜ 0.05 vs. Intermitent, §: p＜ 0.05 vs. Mild persistant, ¶: p＜ 0.05 vs. 
Moderate.
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Table 3 Odds ratio (95%CI) for moderate to severe asthma by subscales of AHQ-Japan or SF-36
SF-36AHQ-Japan
P valueOR (95%CI)subscalesP valueOR（95%CI）subscales
0.04†2.47 (1.08―6.10)
PF
＞＿ mean
＜mean
＜0.01†3.88 (1.67―9.90)
AS
＜mean
＞＿ mean
0.331.47 (0.68―3.32)
RP
＞＿ mean
＜mean
＜0.01†3.21 (1.48―7.32)
FWS
＜mean
＞＿ mean
0.191.65 (0.78―3.60)
BP
＞＿ mean
＜mean
0.02†3.31 (1.32―9.54)
Em
＜mean
＞＿ mean
0.281.50 (0.71―3.21)
GH
＞＿ mean
＜mean
＜0.01†3.94 (1.65―10.58)
DS
＜mean
＞＿ mean
0.661.18 (0.56―2.48)
VT
＞＿ mean
＜mean
0.03†2.75 (1.17―7.03)
SA
＜mean
＞＿ mean
0.301.50 (0.71―3.27)
SF
＞＿ mean
＜mean
0.112.22 (0.87―6.49)
Ec
＜mean
＞＿ mean
0.221.61 (0.76―3.51)
RE
＞＿ mean
＜mean
＜0.01†3.69 (1.59―9.43)
Total score of 32 items
＜mean
＞＿ mean
0.411.36 (0.65―2.87)
MH
＞＿ mean
＜mean
0.511.30 (0.61―2.83)
Face scale
＜mean
＞＿ mean
AS, Asthmatic symptom; FWS, Factors which worsened symptoms; Em, Emotion; DA, Daily activity; SA, Social activity; Ec, Econom-
ics; PF, Physical functioning; RP, Role-physical; BP, Bodily pain; GH, General health; VT, Vitality; SF, Social functioning; RE, Role-emo-
tional; MH, Mental health.
†: p＜0.05.
Table 4 The corelation between subscales of AHQ-Japan or SF-36 and %PEF
p valuernSubscalep valuernSubscale
Evening %PEF vs.Morning %PEF vs.
0.40－0.1437AS0.20－0.2237AS
0.10－0.2837FWS0.04†－0.3337FWS
0.19－0.2237Em0.09－0.2837Em
0.02†－0.3837DA＜0.01†－0.4837DA
0.33－0.1637SA0.29－0.1837SA
0.67－0.0737Ec0.59－0.0937Ec
0.10－0.2837Total score of 32 
items
0.04†－0.3437Total score of 32 
items
0.76－0.0537Face scale0.32－0.1737Face scale
0.090.2836PF0.03†0.3736PF
＜0.01†0.4237RP＜0.01†0.4537RP
0.170.2337BP0.090.2837BP
0.130.2537GH0.04†0.3637GH
0.540.1037VT0.390.1537VT
0.04†0.3437SF0.02†0.3837SF
0.250.2037RE0.220.2137RE
0.420.1437MH0.350.1637MH
r, corelation coeficient; AS, Asthmatic symptom; FWS, Factors which worsened symptoms; Em, Emotion; DA, Daily activity; SA, So-
cial activity; Ec, Economics; PF, Physical functioning; RP, Role-physical; BP, Bodily pain; GH, General health; VT, Vitality; SF, Social 
functioning; RE, Role-emotional; MH, Mental health.
†：p＜0.05 except r of 0 to 土0.2.
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study was carried out using the SF-36 in asthma pa-
tients with disease of varying severity; it was found
that most items were correlated with the severity of
asthma,5 which suggests that such scales may be use-
ful for comparing different populations. The SF-36
(Japanese version) was translated and updated, and it
has been widely used in Japan.13,14 The information
obtained from the SF-36 is important.
The AHQ-33-Japan was developed by the Japanese
Society of Allergology to evaluate HRQOL. In this
study, HRQOL was assessed in Japanese asthma pa-
tients using the AHQ-33 as a disease-specific HRQOL
instrument and the SF-36 as a generic HRQOL instru-
ment. Then, their results were compared to establish
the validity of the AHQ-33.
The present results showed a bias in the score dis-
tribution of the AHQ-33 and indicated a floor effect.
Although this may have been due to the fact that
most patients had symptoms that had stabilized, little
bias was observed in the distribution of the SF-36.
The cause of this difference is unclear, though the pa-
tients may have had certain restrictions.
Although the response rates were excellent for
both instruments, there were a few non-responses
with the SF-36. In the correlation between the
subscales of the AHQ-33 and the SF-36, the SF-36
subscales correlated best with the AHQ-33 Face
Scale. The Face Scale expresses global QOL function-
ing.10 This may explain why there were more correla-
tions between subscales of the SF-36 as a generic
HRQOL instrument and the Face Scale.
In the present study, it was found that the scores of
both QOL instruments worsened as disease severity
increased. However, the relationship between an in-
crease in the AHQ-33 subscale scores and worsening
disease severity (from intermittent to severe) was
more direct than the relationship between a decrease
in the SF-36 subscale scores and worsening severity.
In addition, the odds ratios estimated using the logis-
tic model showed that lower scores in most of the
AHQ-33 subscales were associated with an increased
risk of moderate to severe asthma. Therefore, the
AHQ-33 appears to be more useful and to more accu-
rately reflect disease severity than the SF-36 when
evaluating QOL in Japanese asthma patients. On the
other hand, although several subscales of the AHQ-
33 and the SF-36 correlated with morning %PEF, the
correlation coefficients were low. Lung function data
are often used to evaluate disease severity and treat-
ment effects, but they are poorly correlated with QOL
in asthma patients.11,15,16 This agrees with our re-
sults. Moreover, the number of patients whose PEF
data were evaluated was small in the present study.
Many QOL instruments dealing with asthma have
been developed, including the Asthma Quality of Life
Questionnaire (AQLQ)16-18 and the Living with
Asthma Questionnaire (LWAQ).19 Each instrument
has its own unique form and features. Specific QOL
scales include questions directly related to asthma,
and many of these instruments have been employed
in clinical trials. Van der Molen and colleagues20 re-
ported the discriminative property of two generic
questionnaires (the SF-36 and the Psychological and
General Well Being index (PGWB)) and two asthma-
specific questionnaires (the AQLQ and the LWAQ).
In their cross-sectional comparative study involving
asthma patients, the SF-36 and AQLQ performed bet-
ter than the PGWB and LWAQ. On the other hand,
they reported that the improvement in the quality of
life during a placebo-controlled trial using formoterol
was very small and was only reflected by the LWAQ,
while no improvement in QOL was seen with the SF-
36, the PGWB, and the AQLQ.21
In the future, studies comparing generic HRQOL
instruments, such as the SF-36, and disease-specific
HRQOL instruments, such as the AQLQ and the
LWAQ, are needed to determine their validity and re-
sponsiveness. It is likely that the usefulness of the
AHQ-33 for assessing the HRQOL of asthma patients
will be confirmed. Furthermore, we hope that ver-
sions of the AHQ-33 will be developed for other coun-
tries, and that their use will be studied.
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